FDA Clears Lucamzi Biosimilar for Eye Conditions

The FDA has approved Lucamzi (ranibizumab-blrz), a biosimilar to Lucentis, for treating neovascular age-related macular degeneration, macular edema, and myopic choroidal neovascularization. This approval offers a new intravitreal injection option for these eye conditions, supported by clinical data showing equivalent efficacy and comparable safety to the reference product.